Michael D. Geschwind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael D. Geschwind has a total of 464 co-authors. Here are the top co-authors by number of shared publications:
Katherine Wong
Memory and Aging Center, University of California, San Francisco , San Francisco, CA 94158
6 shared publications- Bruce L. Miller
The Edward and Pearl Fein Memory and Aging Center, Department of Neurology, University of California, San Francisco
5 shared publications Mee-Ohk Kim
Memory and Aging Center, University of California, San Francisco , San Francisco, CA 94158
5 shared publications- Eduardo Caverzasi
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; and
4 shared publications - Leonel Tadao Takada
Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
4 shared publications Bruce L. Miller
Memory and Aging Center, University of California, San Francisco, San Francisco
3 shared publications
Latest Publications
- Open Access
CSF PrP-amyloid seeding predicts clinical onset in inherited prion disease
Silent proteopathic seed propagation is hypothesised to precede neurodegenerative disease, but direct evidence that it signals near-term clinical conversion in humans is lacking. In prion disease, a prototypic disorder of proteopathic seeding, cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) offers a direct measure of prion protein amyloid seeding activity. We analysed longitudinal CSF RT-QuIC data from 94 PRNP E200K mutation carriers across international natural history cohorts to determine whether seeding status predicts clinical conversion. Eleven carriers developed inherited prion disease; all showed at least one positive RT-QuIC result before onset. First positivity appeared a median of 2.0 years prior to symptoms (IQR 1.3–3.3; range 0.2–4.8). Landmark analyses showed RT-QuIC positivity identified a markedly increased short-term conversion risk, whereas persistently asymptomatic carriers remained negative throughout follow-up. These findings establish CSF RT-QuIC positivity as a biomarker-defined state of incipient conversion in E200K carriers, informing risk stratification and preventive trial design.
Open AccessCSF PrP-amyloid seeding predicts clinical onset in inherited prion disease
Silent proteopathic seed propagation is hypothesised to precede neurodegenerative disease, but direct evidence that it signals near-term clinical conversion in humans is lacking. In prion disease, a prototypic disorder of proteopathic seeding, cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) offers a direct measure of prion protein amyloid seeding activity. We analysed longitudinal CSF RT-QuIC data from 94 PRNP E200K mutation carriers across international natural history cohorts to determine whether seeding status predicts clinical conversion. Eleven carriers developed inherited prion disease; all showed at least one positive RT-QuIC result before onset. First positivity appeared a median of 2.0 years prior to symptoms (IQR 1.3–3.3; range 0.2–4.8). Landmark analyses showed RT-QuIC positivity identified a markedly increased short-term conversion risk, whereas persistently asymptomatic carriers remained negative throughout follow-up. These findings establish CSF RT-QuIC positivity as a biomarker-defined state of incipient conversion in E200K carriers, informing risk stratification and preventive trial design.
- Open Access
- 27 October 2026
- Published by Oxford University Press (OUP) in Brain
Short-term outcomes, longer-term disability and relapse risk in LGI1-antibody encephalitis
Leucine-rich glioma-inactivated-1 antibody encephalitis (LGI1-Ab-E) is a common and immunotherapy-responsive form of encephalitis. However, it is not known which immunotherapy regimens improve short-term outcomes, longer-term disability and relapse risk. Further, it is not known if the widely-utilised modified Rankin Scale (mRS) accurately captures quality of life (QoL) in LGI1-Ab-E, complicating disability measurements and interpretation of immunotherapy responses. A multicentre, international, real-world comparative analysis of patients with LGI1-Ab-E. Retrospective data from patient records evaluated short-term seizure and cognitive outcomes, 1-6 year disability, and future relapse risk associations, by integrating demographics, clinical features investigations and exposures to immunotherapies and antiseizure medications (ASMs). Patient- and neurologist-rated QoL assessments were used to establish an evidence-based mRS threshold for defining clinically significant disability. Cox proportional hazard models, Anderson-Gill, and generalised linear mixed-effects models were employed. 181 patients were included, with median age at onset 63 years (range 23 - 92); 122/181 (67%) were male. Short-term outcomes, evaluated at both five and ten weeks post-treatment initiation, identified exposure to immunotherapies associated with seizure resolution (OR = 13.97, 95%CI = 6.10-32.01; p < 0.0001 and OR = 8.53, 95%CI = 4.14-17.55; p < 0.0001, respectively), notably with corticosteroids, plasma exchange and rituximab, but not ASMs, intravenous immunoglobulins or steroid sparing agents. Conversely, seizure recurrence was observed after discontinuation of oral prednisolone, but not other immunotherapies or ASMs (OR = 39.53, 95%CI = 12.70-122.20, p < 0.0001). To evaluate longer-term disability, first, mRS scores were calibrated using QoL assessments: this identified a significant increase in patient-rated disability at mRS score of 2. Hence, using mRS 0-1 as a favourable outcome, we identified worse mRS at nadir associated with greater one-year disability (OR = 2.56, 95%CI = 1.56–4.20, p = 0.0003), and each month of delayed immunotherapy associated with a 16% increased risk of disability (HR = 1.16, 95%CI = 1.06-1.35, p = 0.004). Additionally, absence of immunotherapy associated both with greater one-year disability (OR = 5.67; 95% CI 1.19-26.54, p = 0.03) and a relapsing course (OR = 7.64, 95%CI = 2.51-21.77, p = 0.0002). Both a relapsing course, observed in 38% of patients, and the number of relapses associated with step-wise worsening of disability and QoL-outcomes. Rituximab exposure was the only identified clinical factor associated with reduced future relapse risk, by 93% (HR = 0.07, 95%CI = 0.01-0.48, p = 0.002). Persistent serum LGI1-IgMs, but not LGI1-IgGs, at one-year, associated with future relapses (HR = 11.69, 95%CI = 1.58-145.80, p = 0.02). Distinctive clinical factors and select immunotherapies, particularly intravenous methylprednisolone and plasma exchange, but not ASMs, associated with favourable short-term outcomes, patient-centric longer-term disability and relapses in LGI1-Ab-E. Our findings provide evidence-based disability thresholds, highlight novel prognostic biomarkers, and pragmatically guide LGI1-Ab-E care, pending randomized clinical trials.
- 27 October 2026
- Published by Oxford University Press (OUP) in Brain
Open AccessShort-term outcomes, longer-term disability and relapse risk in LGI1-antibody encephalitis
Leucine-rich glioma-inactivated-1 antibody encephalitis (LGI1-Ab-E) is a common and immunotherapy-responsive form of encephalitis. However, it is not known which immunotherapy regimens improve short-term outcomes, longer-term disability and relapse risk. Further, it is not known if the widely-utilised modified Rankin Scale (mRS) accurately captures quality of life (QoL) in LGI1-Ab-E, complicating disability measurements and interpretation of immunotherapy responses. A multicentre, international, real-world comparative analysis of patients with LGI1-Ab-E. Retrospective data from patient records evaluated short-term seizure and cognitive outcomes, 1-6 year disability, and future relapse risk associations, by integrating demographics, clinical features investigations and exposures to immunotherapies and antiseizure medications (ASMs). Patient- and neurologist-rated QoL assessments were used to establish an evidence-based mRS threshold for defining clinically significant disability. Cox proportional hazard models, Anderson-Gill, and generalised linear mixed-effects models were employed. 181 patients were included, with median age at onset 63 years (range 23 - 92); 122/181 (67%) were male. Short-term outcomes, evaluated at both five and ten weeks post-treatment initiation, identified exposure to immunotherapies associated with seizure resolution (OR = 13.97, 95%CI = 6.10-32.01; p < 0.0001 and OR = 8.53, 95%CI = 4.14-17.55; p < 0.0001, respectively), notably with corticosteroids, plasma exchange and rituximab, but not ASMs, intravenous immunoglobulins or steroid sparing agents. Conversely, seizure recurrence was observed after discontinuation of oral prednisolone, but not other immunotherapies or ASMs (OR = 39.53, 95%CI = 12.70-122.20, p < 0.0001). To evaluate longer-term disability, first, mRS scores were calibrated using QoL assessments: this identified a significant increase in patient-rated disability at mRS score of 2. Hence, using mRS 0-1 as a favourable outcome, we identified worse mRS at nadir associated with greater one-year disability (OR = 2.56, 95%CI = 1.56–4.20, p = 0.0003), and each month of delayed immunotherapy associated with a 16% increased risk of disability (HR = 1.16, 95%CI = 1.06-1.35, p = 0.004). Additionally, absence of immunotherapy associated both with greater one-year disability (OR = 5.67; 95% CI 1.19-26.54, p = 0.03) and a relapsing course (OR = 7.64, 95%CI = 2.51-21.77, p = 0.0002). Both a relapsing course, observed in 38% of patients, and the number of relapses associated with step-wise worsening of disability and QoL-outcomes. Rituximab exposure was the only identified clinical factor associated with reduced future relapse risk, by 93% (HR = 0.07, 95%CI = 0.01-0.48, p = 0.002). Persistent serum LGI1-IgMs, but not LGI1-IgGs, at one-year, associated with future relapses (HR = 11.69, 95%CI = 1.58-145.80, p = 0.02). Distinctive clinical factors and select immunotherapies, particularly intravenous methylprednisolone and plasma exchange, but not ASMs, associated with favourable short-term outcomes, patient-centric longer-term disability and relapses in LGI1-Ab-E. Our findings provide evidence-based disability thresholds, highlight novel prognostic biomarkers, and pragmatically guide LGI1-Ab-E care, pending randomized clinical trials.
- Open Access
Neuropsychiatric Symptom Associations with NOTCH3 Genotype in the United States CADASIL Consortium
Background and objectives: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic cerebral small vessel disease. Though neuropsychiatric symptoms (NPS) of CADASIL profoundly impact function and quality of life, these symptoms remain understudied. This analysis characterizes the prevalence, severity, and profile of NPS among individuals with CADASIL-causing NOTCH3 variants and non-carrier biological family controls in the United States CADASIL Consortium (USCC). Methods: This cross-sectional analysis used multimodal baseline data from 12 enrollment sites across the country. Statistical analyses used nonparametric tests and regression models to compare clinical and neuropsychiatric outcomes across CADASIL risk tiers and controls, adjusting for age, sex, race, and education where appropriate. The primary outcome measure was the Neuropsychiatric Inventory Questionnaire (NPI-Q), an informant-reported measure which assesses 12 categories of NPS. NPI-Q item severity and distress were evaluated for individuals with confirmed cysteine-altering pathogenic NOTCH3 variants and compared with controls. Results: Four hundred fifty-nine USCC participants were included in the analytic cohort: 343 cases [256 high-risk (HR); 63 medium-risk (MR); 24 low-risk (LR)]; and 116 controls. Among participants with available NPI-Q data, at least one neuropsychiatric symptom was reported by 72.6% (n = 228/314) of cases compared with 53.2% (n = 58/109) of controls. Reported symptoms were more common among CADASIL cases than controls, occurring in 75.0%, 71.2%, and 72.7% of participants in the LR, MR, and HR groups, respectively, compared with 53.2% of controls. Compared with controls, participants in the MR group and HR group had higher NPI-Q severity scores. HR participants also had higher NPI-Q distress scores than controls. Discussion: Our findings support the notion that NPS are an important clinical manifestation of CADASIL. Beyond previously reported symptoms, additional neuropsychiatric manifestations were identified. Given the higher burden and variability in the neuropsychiatric presentation of CADASIL, the relationships among neuropsychiatric, neurological, and patient-reported outcomes merit further investigation. The NPS profile may enhance the evaluation of the safety and efficacy of different treatments to target these symptoms for CADASIL patients. Trial Registration Information: The study is registered at ClinicalTrials.gov ( NCT05677880 , 12/12/2022).
Open AccessNeuropsychiatric Symptom Associations with NOTCH3 Genotype in the United States CADASIL Consortium
Background and objectives: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic cerebral small vessel disease. Though neuropsychiatric symptoms (NPS) of CADASIL profoundly impact function and quality of life, these symptoms remain understudied. This analysis characterizes the prevalence, severity, and profile of NPS among individuals with CADASIL-causing NOTCH3 variants and non-carrier biological family controls in the United States CADASIL Consortium (USCC). Methods: This cross-sectional analysis used multimodal baseline data from 12 enrollment sites across the country. Statistical analyses used nonparametric tests and regression models to compare clinical and neuropsychiatric outcomes across CADASIL risk tiers and controls, adjusting for age, sex, race, and education where appropriate. The primary outcome measure was the Neuropsychiatric Inventory Questionnaire (NPI-Q), an informant-reported measure which assesses 12 categories of NPS. NPI-Q item severity and distress were evaluated for individuals with confirmed cysteine-altering pathogenic NOTCH3 variants and compared with controls. Results: Four hundred fifty-nine USCC participants were included in the analytic cohort: 343 cases [256 high-risk (HR); 63 medium-risk (MR); 24 low-risk (LR)]; and 116 controls. Among participants with available NPI-Q data, at least one neuropsychiatric symptom was reported by 72.6% (n = 228/314) of cases compared with 53.2% (n = 58/109) of controls. Reported symptoms were more common among CADASIL cases than controls, occurring in 75.0%, 71.2%, and 72.7% of participants in the LR, MR, and HR groups, respectively, compared with 53.2% of controls. Compared with controls, participants in the MR group and HR group had higher NPI-Q severity scores. HR participants also had higher NPI-Q distress scores than controls. Discussion: Our findings support the notion that NPS are an important clinical manifestation of CADASIL. Beyond previously reported symptoms, additional neuropsychiatric manifestations were identified. Given the higher burden and variability in the neuropsychiatric presentation of CADASIL, the relationships among neuropsychiatric, neurological, and patient-reported outcomes merit further investigation. The NPS profile may enhance the evaluation of the safety and efficacy of different treatments to target these symptoms for CADASIL patients. Trial Registration Information: The study is registered at ClinicalTrials.gov ( NCT05677880 , 12/12/2022).
- Open Access
The United States CADASIL Consortium: Baseline Findings from a Natural History Study
Background and Objectives: Vascular contributions to cognitive impairment and dementia (VCID) represent the second leading cause of dementia and a common comorbidity for reduced functional capacity in many individuals, but clinical management and clinical trial readiness are severely hindered by extreme phenotypic and mechanistic heterogeneity. This study establishes the baseline clinical, functional, and multimodal biomarker characteristics of the first United States (US) cohort of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), serving as a single-cause, monogenic small vessel disease model for sporadic VCID. Methods: Cross-sectional analysis of baseline data collected from October 2022 through January 2025 from a longitudinal cohort at 12 US enrollment sites. Adults from families with a documented NOTCH3 variant were recruited through clinical referrals, medical record review, advocacy organizations, and community outreach. Exclusion criteria included other conditions that prevented interpretation of findings and modified Rankin Scale (mRS) scores greater than 3. Central genetic characterization assigned persons with a pathogenic or likely pathogenic NOTCH3 variant to low-, medium-, or high-risk tiers based on epidermal growth factor-like repeat domains. Standardized assessments included clinical histories, exams, objective cognitive and physical assessments, self-reported, companion-reported, and clinician-rated measures, MRI, genetics, and proteomics acquired under harmonized protocols. Group comparisons used Fishers exact and Kruskal–Wallis tests. Multivariable regression used adjustment for age, sex, race, and education. Results: Of 560 participants completing baseline visits, 46 had variants of unknown significance, and 55 had pending genetic analyses. The analytic cohort included 343 persons with a CADASIL-causing NOTCH3 variant and 116 non-carrier family controls. Median age was 47.9 years (IQR 38.7–59.1), median education was 16 years (IQR 14– 17), 62.5% were female, and 91.4% were White. Carriers were classified in CADASIL risk tiers: low (7.0%), medium (18.4%), or high (74.6%). Compared with controls, adjusted odds of classification into a more impaired CDR category were higher in all tiers (OR 2.55-5.08, 95% CI 1.22–11.34). Discussion: The US CADASIL Consortium has established a large, genetics-confirmed cohort spanning presymptomatic to moderate disease stages, providing a robust, harmonized platform to define early biomarker signatures and endpoints for targeted VCID therapies.
Open AccessThe United States CADASIL Consortium: Baseline Findings from a Natural History Study
Background and Objectives: Vascular contributions to cognitive impairment and dementia (VCID) represent the second leading cause of dementia and a common comorbidity for reduced functional capacity in many individuals, but clinical management and clinical trial readiness are severely hindered by extreme phenotypic and mechanistic heterogeneity. This study establishes the baseline clinical, functional, and multimodal biomarker characteristics of the first United States (US) cohort of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), serving as a single-cause, monogenic small vessel disease model for sporadic VCID. Methods: Cross-sectional analysis of baseline data collected from October 2022 through January 2025 from a longitudinal cohort at 12 US enrollment sites. Adults from families with a documented NOTCH3 variant were recruited through clinical referrals, medical record review, advocacy organizations, and community outreach. Exclusion criteria included other conditions that prevented interpretation of findings and modified Rankin Scale (mRS) scores greater than 3. Central genetic characterization assigned persons with a pathogenic or likely pathogenic NOTCH3 variant to low-, medium-, or high-risk tiers based on epidermal growth factor-like repeat domains. Standardized assessments included clinical histories, exams, objective cognitive and physical assessments, self-reported, companion-reported, and clinician-rated measures, MRI, genetics, and proteomics acquired under harmonized protocols. Group comparisons used Fishers exact and Kruskal–Wallis tests. Multivariable regression used adjustment for age, sex, race, and education. Results: Of 560 participants completing baseline visits, 46 had variants of unknown significance, and 55 had pending genetic analyses. The analytic cohort included 343 persons with a CADASIL-causing NOTCH3 variant and 116 non-carrier family controls. Median age was 47.9 years (IQR 38.7–59.1), median education was 16 years (IQR 14– 17), 62.5% were female, and 91.4% were White. Carriers were classified in CADASIL risk tiers: low (7.0%), medium (18.4%), or high (74.6%). Compared with controls, adjusted odds of classification into a more impaired CDR category were higher in all tiers (OR 2.55-5.08, 95% CI 1.22–11.34). Discussion: The US CADASIL Consortium has established a large, genetics-confirmed cohort spanning presymptomatic to moderate disease stages, providing a robust, harmonized platform to define early biomarker signatures and endpoints for targeted VCID therapies.
- Top Cited Papers
- 13 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (1) , e214439
Standardizing “Rapid”
Rapidly progressive dementia (RPD) accounts for 3%-4% of dementia cases yet presents a disproportionate clinical challenge given the wide differential diagnosis and the need to quickly identify potentially treatment-responsive causes. The lack of a standardized definition of RPD challenges generalization of published findings and precludes multisite studies. We sought to determine whether a standardized definition, based on the Clinical Dementia Rating (CDR), could reliably distinguish individuals with a broad spectrum of causes of RPD early in the symptomatic course. RPD was defined as dementia (global CDR ≥1) developing within 1 year or incapacitation (global CDR ≥2) within 2 years of symptom onset. Patients with suspected RPD were referred from inpatient and outpatient settings at Mayo Clinic in Florida (Jacksonville, FL) and Washington University in St. Louis (Saint Louis, MO) and prospectively evaluated (RaPID cohort). Retrospective data from participants assessed across 46 research centers were also analyzed (National Alzheimer's Coordinating Center [NACC] data set). Characteristics and rates of progression (main outcome) were compared between typically progressive and RPD. Univariable and multivariable analyses were performed using Mann-Whitney U/Kruskal-Wallis (continuous) and Fisher exact/χ2 tests (binary), respectively. Our definition of RPD was compared against definitions identified through a scoping review conducted using a validated 6-stage approach. In the RaPID cohort, 185 of 248 (74.6%) patients met our CDR-based RPD definition (median [range] age-at-symptom onset: 68.8 years [22.0-90.7]; 45.4% female). Autoimmune (55/185, 29.7%), neurodegenerative (51/185, 27.6%), and prion diseases (35/185, 18.9%) predominated. Among 20,418 NACC participants with cognitive impairment, 836 (4.1%) met our RPD definition (median [range] age-at-symptom onset: 74 years [24-103]; 57.1% female). Neurodegenerative diseases predominated, especially Alzheimer disease (485/836, 58.0%). Individuals with RPD declined substantially faster (ΔCDR sum-of-boxes/year: RaPID, 14.4 ± 5.3 vs 4.3 ± 4.3, p < 0.001; NACC, 6.7 ± 3.1 vs 1.7 ± 1.4, p < 0.001). Our scoping review identified 22 studies that applied 10 distinct definitions of RPD. Uniquely, our CDR-based definition clearly distinguished individuals with a broad spectrum of causes of RPD, assessed across multiple sites/settings, supporting early diagnosis with minimal resource requirements. The CDR-based definition of RPD effectively identified individuals with a broad spectrum of causes of RPD early in the symptomatic course. The need for training and time to reliably administer the CDR may limit application of the proposed definition of RPD. Validation in additional cohorts is required to support generalizability.
- 13 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (1) , e214439
Top Cited PapersStandardizing “Rapid”
Rapidly progressive dementia (RPD) accounts for 3%-4% of dementia cases yet presents a disproportionate clinical challenge given the wide differential diagnosis and the need to quickly identify potentially treatment-responsive causes. The lack of a standardized definition of RPD challenges generalization of published findings and precludes multisite studies. We sought to determine whether a standardized definition, based on the Clinical Dementia Rating (CDR), could reliably distinguish individuals with a broad spectrum of causes of RPD early in the symptomatic course. RPD was defined as dementia (global CDR ≥1) developing within 1 year or incapacitation (global CDR ≥2) within 2 years of symptom onset. Patients with suspected RPD were referred from inpatient and outpatient settings at Mayo Clinic in Florida (Jacksonville, FL) and Washington University in St. Louis (Saint Louis, MO) and prospectively evaluated (RaPID cohort). Retrospective data from participants assessed across 46 research centers were also analyzed (National Alzheimer's Coordinating Center [NACC] data set). Characteristics and rates of progression (main outcome) were compared between typically progressive and RPD. Univariable and multivariable analyses were performed using Mann-Whitney U/Kruskal-Wallis (continuous) and Fisher exact/χ2 tests (binary), respectively. Our definition of RPD was compared against definitions identified through a scoping review conducted using a validated 6-stage approach. In the RaPID cohort, 185 of 248 (74.6%) patients met our CDR-based RPD definition (median [range] age-at-symptom onset: 68.8 years [22.0-90.7]; 45.4% female). Autoimmune (55/185, 29.7%), neurodegenerative (51/185, 27.6%), and prion diseases (35/185, 18.9%) predominated. Among 20,418 NACC participants with cognitive impairment, 836 (4.1%) met our RPD definition (median [range] age-at-symptom onset: 74 years [24-103]; 57.1% female). Neurodegenerative diseases predominated, especially Alzheimer disease (485/836, 58.0%). Individuals with RPD declined substantially faster (ΔCDR sum-of-boxes/year: RaPID, 14.4 ± 5.3 vs 4.3 ± 4.3, p < 0.001; NACC, 6.7 ± 3.1 vs 1.7 ± 1.4, p < 0.001). Our scoping review identified 22 studies that applied 10 distinct definitions of RPD. Uniquely, our CDR-based definition clearly distinguished individuals with a broad spectrum of causes of RPD, assessed across multiple sites/settings, supporting early diagnosis with minimal resource requirements. The CDR-based definition of RPD effectively identified individuals with a broad spectrum of causes of RPD early in the symptomatic course. The need for training and time to reliably administer the CDR may limit application of the proposed definition of RPD. Validation in additional cohorts is required to support generalizability.
- 28 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1268-1277
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3
The READISCA study aims to prepare for clinical trials in spinocerebellar ataxia types 1 and 3 (SCA1 and SCA3). Hence, we searched for predictive variables of ataxia onset (phenoconversion) and progression. Individuals with SCA1 or SCA3 and controls were enrolled from 2018 to 2021 in the USA and Europe. Clinical scores, MRI measures and neurofilament light chain (NfL) levels were assessed annually for 5 years. In the pre-ataxic group at baseline, we compared phenoconverters with non-converters. A Bayesian mixed model was used to model the longitudinal progression of clinical scores and NfL levels. The impact of data-driven selected baseline variables (demographic, clinical and MRI) on the expected Scale for Assessment and Rating of Ataxia progression was tested. Forty-three controls, 55 SCA1 carriers and 124 SCA3 carriers were included; a subset of the cohort (n = 109) had MRI data. Converters from pre-ataxic to ataxic stages represented 5/22 (22%) and 12/38 (32%) for SCA1 and SCA3, respectively. Converters were more depressed (Patient Health Questionnaire 9: 3.9 ± 2.9 versus 2.3 ± 2.6, P = 0.04), had higher plasma NfL levels (17.6 ± 5.7 versus 11.1 ± 5.9 pg/ml, P < 0.0001), more cerebellar white matter atrophy (1.44% ± 0.12% of total intracranial volume versus 1.54% ± 0.16%, P = 0.032) and more Inventory of Non-Ataxia Signs signs (1.8 ± 1.3 versus 0.7 ± 0.8, P = 0.002). All clinical scores except Cerebellar Cognitive Affective Syndrome significantly worsened during the study. NfL levels significantly increased in non-converters and ataxic SCA3 (1.06 ± 0.33 pg/ml/year, P = 0.002 and 0.57 ± 0.21 pg/ml/year, P = 0.01, respectively) but not in controls and ataxic SCA1 (0.31 ± 0.26 pg/ml/year, P = 0.24 and 0.26 ± 0.42 pg/ml/year, P = 0.55, respectively). In the best predictive model of Scale for Assessment and Rating of Ataxia progression after 1 year (R2 = 0.54), factors linked with faster progression were higher functional stage (P < 0.001), higher Composite Cerebellar Functional Score (P = 0.002) and higher total creatine in cerebellar white matter (P = 0.026). Factors significantly linked to conversion, namely NfL levels, depression and lower motor neuron involvement, differ from those driving disease progression. The NfL levels and lower motor neuron signs could be used as predictors of phenoconversion and MRI variables as ataxia progression predictors. Psychological care should be provided in the pre-ataxic phase of the disease.
- 28 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1268-1277
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3
The READISCA study aims to prepare for clinical trials in spinocerebellar ataxia types 1 and 3 (SCA1 and SCA3). Hence, we searched for predictive variables of ataxia onset (phenoconversion) and progression. Individuals with SCA1 or SCA3 and controls were enrolled from 2018 to 2021 in the USA and Europe. Clinical scores, MRI measures and neurofilament light chain (NfL) levels were assessed annually for 5 years. In the pre-ataxic group at baseline, we compared phenoconverters with non-converters. A Bayesian mixed model was used to model the longitudinal progression of clinical scores and NfL levels. The impact of data-driven selected baseline variables (demographic, clinical and MRI) on the expected Scale for Assessment and Rating of Ataxia progression was tested. Forty-three controls, 55 SCA1 carriers and 124 SCA3 carriers were included; a subset of the cohort (n = 109) had MRI data. Converters from pre-ataxic to ataxic stages represented 5/22 (22%) and 12/38 (32%) for SCA1 and SCA3, respectively. Converters were more depressed (Patient Health Questionnaire 9: 3.9 ± 2.9 versus 2.3 ± 2.6, P = 0.04), had higher plasma NfL levels (17.6 ± 5.7 versus 11.1 ± 5.9 pg/ml, P < 0.0001), more cerebellar white matter atrophy (1.44% ± 0.12% of total intracranial volume versus 1.54% ± 0.16%, P = 0.032) and more Inventory of Non-Ataxia Signs signs (1.8 ± 1.3 versus 0.7 ± 0.8, P = 0.002). All clinical scores except Cerebellar Cognitive Affective Syndrome significantly worsened during the study. NfL levels significantly increased in non-converters and ataxic SCA3 (1.06 ± 0.33 pg/ml/year, P = 0.002 and 0.57 ± 0.21 pg/ml/year, P = 0.01, respectively) but not in controls and ataxic SCA1 (0.31 ± 0.26 pg/ml/year, P = 0.24 and 0.26 ± 0.42 pg/ml/year, P = 0.55, respectively). In the best predictive model of Scale for Assessment and Rating of Ataxia progression after 1 year (R2 = 0.54), factors linked with faster progression were higher functional stage (P < 0.001), higher Composite Cerebellar Functional Score (P = 0.002) and higher total creatine in cerebellar white matter (P = 0.026). Factors significantly linked to conversion, namely NfL levels, depression and lower motor neuron involvement, differ from those driving disease progression. The NfL levels and lower motor neuron signs could be used as predictors of phenoconversion and MRI variables as ataxia progression predictors. Psychological care should be provided in the pre-ataxic phase of the disease.
- 28 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (1) , 262-273
Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease
Although neuropsychiatric symptoms are not part of diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD), a few retrospective studies and our clinical experience have suggested they are prominent and often occur early. The objective of our study was to assess prospectively the neuropsychiatric features in sCJD (and their impact on caregivers) and compare them with five other neurodegenerative diseases: Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), progressive supranuclear palsy, behavioural variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia. The Neuropsychiatric Inventory (NPI) was given at the first UCSF research visit to caregivers of 789 serial patients evaluated at the UCSF Memory and Aging Center from January 2000 through November 2016 who met the diagnostic research criteria for one of these six neurodegenerative disorders. All subjects underwent a Mini-Mental State Examination, and demographic data (age, sex, years of education) were collected. We hypothesized that sCJD has a very prominent behavioural and neuropsychiatric profile, which might help to distinguish it from other neurodegenerative diseases. Of our sCJD cohort (n = 92), 97% exhibited at least one and 50% at least six of the 12 symptoms on the NPI at the time of their first research visit. The most common behavioural symptoms, which occurred in >50% of the sCJD patient cohort, were: appetite/eating disturbances (68%), apathy/indifference (66%), night-time behaviour disturbances (53%), aberrant motor behaviour (53%) and anxiety (52%). Even the least common behaviour, disinhibition, occurred in 19%. Compared with DLB and bvFTD, two conditions with very prominent behavioural features that are included in their diagnostic criteria, sCJD had significantly higher mean NPI frequency × severity scores for night-time behaviour disturbances and delusions. Patients with sCJD scored higher for hallucinations and dysphoria than bvFTD patients and higher for appetite/eating disturbances, aberrant motor behaviour and agitation than patients with DLB. sCJD resulted in significantly worse frequency × severity scores than AD in nine of the NPI symptom domains, with our data revealing sCJD to be a highly behavioural syndrome. No neuropsychiatric symptom is pathognomonic for sCJD, but specific symptoms may enable the differentiation of sCJD from other neurodegenerative diseases. Our findings support the inclusion of behavioural symptoms in sCJD diagnostic criteria.
- 28 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (1) , 262-273
Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease
Although neuropsychiatric symptoms are not part of diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD), a few retrospective studies and our clinical experience have suggested they are prominent and often occur early. The objective of our study was to assess prospectively the neuropsychiatric features in sCJD (and their impact on caregivers) and compare them with five other neurodegenerative diseases: Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), progressive supranuclear palsy, behavioural variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia. The Neuropsychiatric Inventory (NPI) was given at the first UCSF research visit to caregivers of 789 serial patients evaluated at the UCSF Memory and Aging Center from January 2000 through November 2016 who met the diagnostic research criteria for one of these six neurodegenerative disorders. All subjects underwent a Mini-Mental State Examination, and demographic data (age, sex, years of education) were collected. We hypothesized that sCJD has a very prominent behavioural and neuropsychiatric profile, which might help to distinguish it from other neurodegenerative diseases. Of our sCJD cohort (n = 92), 97% exhibited at least one and 50% at least six of the 12 symptoms on the NPI at the time of their first research visit. The most common behavioural symptoms, which occurred in >50% of the sCJD patient cohort, were: appetite/eating disturbances (68%), apathy/indifference (66%), night-time behaviour disturbances (53%), aberrant motor behaviour (53%) and anxiety (52%). Even the least common behaviour, disinhibition, occurred in 19%. Compared with DLB and bvFTD, two conditions with very prominent behavioural features that are included in their diagnostic criteria, sCJD had significantly higher mean NPI frequency × severity scores for night-time behaviour disturbances and delusions. Patients with sCJD scored higher for hallucinations and dysphoria than bvFTD patients and higher for appetite/eating disturbances, aberrant motor behaviour and agitation than patients with DLB. sCJD resulted in significantly worse frequency × severity scores than AD in nine of the NPI symptom domains, with our data revealing sCJD to be a highly behavioural syndrome. No neuropsychiatric symptom is pathognomonic for sCJD, but specific symptoms may enable the differentiation of sCJD from other neurodegenerative diseases. Our findings support the inclusion of behavioural symptoms in sCJD diagnostic criteria.
- Open Access
- 2 January 2024
- Published by Springer Nature in The Cerebellum
- Vol. 23 (4) , 1411-1425
The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar Ataxias
The Cerebellar Cognitive Affective/Schmahmann Syndrome (CCAS) manifests as impaired executive control, linguistic processing, visual spatial function, and affect regulation. The CCAS has been described in the spinocerebellar ataxias (SCAs), but its prevalence is unknown. We analyzed results of the CCAS/Schmahmann Scale (CCAS-S), developed to detect and quantify CCAS, in two natural history studies of 309 individuals Symptomatic for SCA1, SCA2, SCA3, SCA6, SCA7, or SCA8, 26 individuals Pre-symptomatic for SCA1 or SCA3, and 37 Controls. We compared total raw scores, domain scores, and total fail scores between Symptomatic, Pre-symptomatic, and Control cohorts, and between SCA types. We calculated scale sensitivity and selectivity based on CCAS category designation among Symptomatic individuals and Controls, and correlated CCAS-S performance against age and education, and in Symptomatic patients, against genetic repeat length, onset age, disease duration, motor ataxia, depression, and fatigue. Definite CCAS was identified in 46% of the Symptomatic group. False positive rate among Controls was 5.4%. Symptomatic individuals had poorer global CCAS-S performance than Controls, accounting for age and education. The domains of semantic fluency, phonemic fluency, and category switching that tap executive function and linguistic processing consistently separated Symptomatic individuals from Controls. CCAS-S scores correlated most closely with motor ataxia. Controls were similar to Pre-symptomatic individuals whose nearness to symptom onset was unknown. The use of the CCAS-S identifies a high CCAS prevalence in a large cohort of SCA patients, underscoring the utility of the scale and the notion that the CCAS is the third cornerstone of clinical ataxiology.
- 2 January 2024
- Published by Springer Nature in The Cerebellum
- Vol. 23 (4) , 1411-1425
Open AccessThe Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar Ataxias
The Cerebellar Cognitive Affective/Schmahmann Syndrome (CCAS) manifests as impaired executive control, linguistic processing, visual spatial function, and affect regulation. The CCAS has been described in the spinocerebellar ataxias (SCAs), but its prevalence is unknown. We analyzed results of the CCAS/Schmahmann Scale (CCAS-S), developed to detect and quantify CCAS, in two natural history studies of 309 individuals Symptomatic for SCA1, SCA2, SCA3, SCA6, SCA7, or SCA8, 26 individuals Pre-symptomatic for SCA1 or SCA3, and 37 Controls. We compared total raw scores, domain scores, and total fail scores between Symptomatic, Pre-symptomatic, and Control cohorts, and between SCA types. We calculated scale sensitivity and selectivity based on CCAS category designation among Symptomatic individuals and Controls, and correlated CCAS-S performance against age and education, and in Symptomatic patients, against genetic repeat length, onset age, disease duration, motor ataxia, depression, and fatigue. Definite CCAS was identified in 46% of the Symptomatic group. False positive rate among Controls was 5.4%. Symptomatic individuals had poorer global CCAS-S performance than Controls, accounting for age and education. The domains of semantic fluency, phonemic fluency, and category switching that tap executive function and linguistic processing consistently separated Symptomatic individuals from Controls. CCAS-S scores correlated most closely with motor ataxia. Controls were similar to Pre-symptomatic individuals whose nearness to symptom onset was unknown. The use of the CCAS-S identifies a high CCAS prevalence in a large cohort of SCA patients, underscoring the utility of the scale and the notion that the CCAS is the third cornerstone of clinical ataxiology.
- Open Access
Enlarged Perivascular Spaces are Associated with White Matter Injury, Brain Atrophy, Cognitive Decline and Markers of Inflammation in an Autosomal Dominant Vascular Neurodegenerative Disease (CADASIL)
Background and Objectives: Enlarged perivascular spaces (ePVS) have been previously reported in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy (CADASIL), but their significance and pathophysiology remains unclear. We investigated associations of ePVS with classical imaging measures, cognitive measures and plasma proteins to better understand what ePVS represents in CADASIL and whether radiographic measures of ePVS would be of value in future therapeutic discovery studies for CADASIL. Methods: 24 individuals with CADASIL and 24 age and sex matched controls were included. Disease status was determined based on presence of NOTCH3 mutation. Brain imaging measures of white matter hyperintensity (WMH), brain parenchymal fraction (BPF), ePVS volumes, clinical, and cognitive measures, as well as plasma proteomics were used in models. Global ePVS volumes were calculated via a novel, semi-automated pipeline and levels of 7363 proteins were quantified in plasma using the SomaScan assay. The relationship of ePVS with global burden of WMH, brain atrophy, functional status, neurocognitive measures, and plasma proteins were modelled with linear regression models. Results: CADASIL and control groups did not exhibit differences in mean ePVS volumes. However, increased ePVS volumes in CADASIL were associated with increased WMH volume (β=0.57, p=0.05), Clinical Dementia Rating (CDR) Sum-of-Boxes score (β=0.49, p=0.04), and decreased brain parenchymal fraction (BPF) (β=-0.03, p=0.10). In interaction term models, the interaction term between CADASIL disease status and ePVS volume was associated with increased WMH volume (β=0.57, p=0.02), Clinical Dementia Rating (CDR) Sum-of-Boxes score (β=0.52, p=0.02), decreased BPF (β=-0.03, p=0.07) and Mini Mental State Examination (MMSE) score (β=-1.49, p=0.03). Proteins positively associated with ePVS volumes were found to be related to leukocyte migration and inflammation, while negatively associated proteins were related to lipid metabolism. Two central hub proteins were identified in protein networks associated with ePVS volumes: CXCL8/IL-8, and CCL2/MCP-1. The levels of CXCL8/IL8 were also associated with increased WMH volume (β=2.44, p < 0.01), and levels of CCL2/MCP-1 were further associated with decreased BPF (β=-0.0007, p < 0.01), MMSE score (β=-0.02, p < 0.01), and increased Trail Making Test B (TRAILB) completion time (β=0.76, p < 0.01). No protein was associated with all 3 studied imaging measures of pathology (BPF,ePVS,WMH). Discussion: Based on associations uncovered between ePVS volumes and cognitive functions, imaging and plasma proteins, we conclude that ePVS volumes capture pathologies contributing to chronic brain dysfunction and degeneration in CADASIL, with relevance to future clinical trials for novel therapeutic discoveries to prevent decline and injury in individuals carrying NOTCH3 mutations.
Open AccessEnlarged Perivascular Spaces are Associated with White Matter Injury, Brain Atrophy, Cognitive Decline and Markers of Inflammation in an Autosomal Dominant Vascular Neurodegenerative Disease (CADASIL)
Background and Objectives: Enlarged perivascular spaces (ePVS) have been previously reported in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy (CADASIL), but their significance and pathophysiology remains unclear. We investigated associations of ePVS with classical imaging measures, cognitive measures and plasma proteins to better understand what ePVS represents in CADASIL and whether radiographic measures of ePVS would be of value in future therapeutic discovery studies for CADASIL. Methods: 24 individuals with CADASIL and 24 age and sex matched controls were included. Disease status was determined based on presence of NOTCH3 mutation. Brain imaging measures of white matter hyperintensity (WMH), brain parenchymal fraction (BPF), ePVS volumes, clinical, and cognitive measures, as well as plasma proteomics were used in models. Global ePVS volumes were calculated via a novel, semi-automated pipeline and levels of 7363 proteins were quantified in plasma using the SomaScan assay. The relationship of ePVS with global burden of WMH, brain atrophy, functional status, neurocognitive measures, and plasma proteins were modelled with linear regression models. Results: CADASIL and control groups did not exhibit differences in mean ePVS volumes. However, increased ePVS volumes in CADASIL were associated with increased WMH volume (β=0.57, p=0.05), Clinical Dementia Rating (CDR) Sum-of-Boxes score (β=0.49, p=0.04), and decreased brain parenchymal fraction (BPF) (β=-0.03, p=0.10). In interaction term models, the interaction term between CADASIL disease status and ePVS volume was associated with increased WMH volume (β=0.57, p=0.02), Clinical Dementia Rating (CDR) Sum-of-Boxes score (β=0.52, p=0.02), decreased BPF (β=-0.03, p=0.07) and Mini Mental State Examination (MMSE) score (β=-1.49, p=0.03). Proteins positively associated with ePVS volumes were found to be related to leukocyte migration and inflammation, while negatively associated proteins were related to lipid metabolism. Two central hub proteins were identified in protein networks associated with ePVS volumes: CXCL8/IL-8, and CCL2/MCP-1. The levels of CXCL8/IL8 were also associated with increased WMH volume (β=2.44, p < 0.01), and levels of CCL2/MCP-1 were further associated with decreased BPF (β=-0.0007, p < 0.01), MMSE score (β=-0.02, p < 0.01), and increased Trail Making Test B (TRAILB) completion time (β=0.76, p < 0.01). No protein was associated with all 3 studied imaging measures of pathology (BPF,ePVS,WMH). Discussion: Based on associations uncovered between ePVS volumes and cognitive functions, imaging and plasma proteins, we conclude that ePVS volumes capture pathologies contributing to chronic brain dysfunction and degeneration in CADASIL, with relevance to future clinical trials for novel therapeutic discoveries to prevent decline and injury in individuals carrying NOTCH3 mutations.
- Open Access
- 6 June 2022
- Published by Wiley in Human Brain Mapping
- Vol. 43 (13) , 4158-4173
Default Mode Network quantitative diffusion and resting‐state functional magnetic resonance imaging correlates in sporadic Creutzfeldt‐Jakob disease
Grey matter involvement is a well‐known feature in sporadic Creutzfeldt–Jakob disease (sCJD), yet precise anatomy‐based quantification of reduced diffusivity is still not fully understood. Default Mode Network (DMN) areas have been recently demonstrated as selectively involved in sCJD, and functional connectivity has never been investigated in prion diseases. We analyzed the grey matter involvement using a quantitatively multi‐parametric MRI approach. Specifically, grey matter mean diffusivity of 37 subjects with sCJD was compared with that of 30 age‐matched healthy controls with a group‐wise approach. Differences in mean diffusivity were also examined between the cortical (MM(V)1, MM(V)2C, and VV1) and subcortical (VV2 and MV2K) subgroups of sCJD for those with autopsy data available (n = 27, 73%). We also assessed resting‐state functional connectivity of both ventral and dorsal components of DMN in a subset of subject with a rs‐fMRI dataset available (n = 17). Decreased diffusivity was predominantly present in posterior cortical regions of the DMN, but also outside of the DMN in temporal areas and in a few limbic and frontal areas, in addition to extensive deep nuclei involvement. Both subcortical and cortical sCJD subgroups showed decreased diffusivity subcortically, whereas only the cortical type expressed significantly decreased diffusivity cortically, mainly in parietal, occipital, and medial‐inferior temporal cortices bilaterally. Interestingly, we found abnormally increased connectivity in both dorsal and ventral components of the DMN in sCJD subjects compared with healthy controls. The significance and possible utility of functional imaging as a biomarker for tracking disease progression in prion disease needs to be explored further.
- 6 June 2022
- Published by Wiley in Human Brain Mapping
- Vol. 43 (13) , 4158-4173
Open AccessDefault Mode Network quantitative diffusion and resting‐state functional magnetic resonance imaging correlates in sporadic Creutzfeldt‐Jakob disease
Grey matter involvement is a well‐known feature in sporadic Creutzfeldt–Jakob disease (sCJD), yet precise anatomy‐based quantification of reduced diffusivity is still not fully understood. Default Mode Network (DMN) areas have been recently demonstrated as selectively involved in sCJD, and functional connectivity has never been investigated in prion diseases. We analyzed the grey matter involvement using a quantitatively multi‐parametric MRI approach. Specifically, grey matter mean diffusivity of 37 subjects with sCJD was compared with that of 30 age‐matched healthy controls with a group‐wise approach. Differences in mean diffusivity were also examined between the cortical (MM(V)1, MM(V)2C, and VV1) and subcortical (VV2 and MV2K) subgroups of sCJD for those with autopsy data available (n = 27, 73%). We also assessed resting‐state functional connectivity of both ventral and dorsal components of DMN in a subset of subject with a rs‐fMRI dataset available (n = 17). Decreased diffusivity was predominantly present in posterior cortical regions of the DMN, but also outside of the DMN in temporal areas and in a few limbic and frontal areas, in addition to extensive deep nuclei involvement. Both subcortical and cortical sCJD subgroups showed decreased diffusivity subcortically, whereas only the cortical type expressed significantly decreased diffusivity cortically, mainly in parietal, occipital, and medial‐inferior temporal cortices bilaterally. Interestingly, we found abnormally increased connectivity in both dorsal and ventral components of the DMN in sCJD subjects compared with healthy controls. The significance and possible utility of functional imaging as a biomarker for tracking disease progression in prion disease needs to be explored further.